Compass Therapeutics, Inc. CMPX
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -85.71%
- 1 year
- -79.48%
- Open
- 0.8112
- Prev close
- 0.7865
- Mkt cap
- 138.22M
- Vol
- 2.11M
- Avg vol
- 4.28M
- EPS
- -0.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7501
- High
- 0.8112
- Forward P/E
- -10.86
- Beta
- 1.30
- Short ratio
- 12.39
- Inst. own
- 88.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.68
- 200-d avg
- 4.58
- 1y target
- 13.64
MAX chart
Events in this range
- Dec 3, 2025Rating: Canaccord Genuity · — → Buy
- Dec 3, 2025Rating: Citizens · — → Market Outperform
- Dec 3, 2025Rating: Cantor Fitzgerald · — → Overweight
- Jan 5, 2026Rating: William Blair · — → Outperform
- Jan 6, 2026Rating: D. Boral Capital · Buy → Buy
- Mar 24, 2026Rating: Guggenheim · Buy → Buy
Signals (86)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| RSI: Oversold | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| RSI: Oversold | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 23, 2026 | 8 months ago |
| RSI: Overbought | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| RSI: Overbought | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bearish | Mar 24, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 13, 2025 | 1 year ago |
| RSI: Overbought | Jan 13, 2025 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| SMA: Bullish | Dec 23, 2024 | 1 year ago |
| SMA: Bearish | Dec 16, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 9, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| SMA: Bearish | Oct 28, 2024 | 2 years ago |
| SMA: Bullish | Sep 9, 2024 | 2 years ago |
| SMA: Bearish | Sep 2, 2024 | 2 years ago |
| SMA: Bullish | Aug 26, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 12, 2024 | 2 years ago |
| SMA: Bullish | Aug 5, 2024 | 2 years ago |
| RSI: Oversold | Jul 1, 2024 | 2 years ago |
| MACD: Sell Signal | May 20, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| SMA: Bullish | Feb 5, 2024 | 2 years ago |
| RSI: Oversold | Jan 29, 2024 | 2 years ago |
| SMA: Bearish | Jan 15, 2024 | 2 years ago |
| SMA: Bullish | Jan 8, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 4, 2023 | 2 years ago |
| RSI: Oversold | Nov 6, 2023 | 2 years ago |
| RSI: Oversold | Sep 11, 2023 | 3 years ago |
| SMA: Bearish | Jul 3, 2023 | 3 years ago |
| SMA: Bullish | Jun 19, 2023 | 3 years ago |
| SMA: Bearish | Jun 12, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| SMA: Bearish | May 15, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| SMA: Bearish | Feb 27, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 23, 2023 | 3 years ago |
| SMA: Bearish | Jan 16, 2023 | 3 years ago |
| RSI: Overbought | Dec 19, 2022 | 3 years ago |
| RSI: Overbought | Nov 28, 2022 | 3 years ago |
| RSI: Overbought | Nov 7, 2022 | 3 years ago |
| MACD: Buy Signal | Oct 10, 2022 | 4 years ago |
| SMA: Bullish | Oct 3, 2022 | 4 years ago |
| SMA: Bullish | Oct 3, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 26, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| SMA: Bullish | May 9, 2022 | 4 years ago |
| SMA: Bullish | May 2, 2022 | 4 years ago |
| MACD: Buy Signal | Apr 11, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 28, 2022 | 4 years ago |
| RSI: Oversold | Feb 21, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 14, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 31, 2022 | 4 years ago |
| RSI: Oversold | Jan 10, 2022 | 4 years ago |
| SMA: Bearish | Nov 22, 2021 | 4 years ago |
| RSI: Oversold | Nov 15, 2021 | 4 years ago |
| SMA: Bullish | Nov 1, 2021 | 5 years ago |
| SMA: Bearish | Jul 19, 2021 | 5 years ago |
| SMA: Bullish | Jul 5, 2021 | 5 years ago |
News
8 hours ago globenewswire.com
Compass Therapeutics to Participate in Upcoming November Investor Events
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
1 week ago globenewswire.com
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
BOSTON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
2 weeks ago globenewswire.com
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
1 month ago benzinga.com
This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.
-
1 month ago benzinga.com
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8
Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.
1 month ago seekingalpha.com
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity
Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance…
1 month ago benzinga.com
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.
-
1 month ago benzinga.com
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4
Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4
Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $8 to $4.
-
1 month ago benzinga.com
Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1
Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Lowers Price Target to $12
HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $24 to $12.
1 month ago benzinga.com
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
1 month ago benzinga.com
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program.
1 month ago benzinga.com
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
Compass Therapeutics shares plunge after FDA seeks a survival-benefit trial before tovecimig’s FDA marketing application.
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved…
1 month ago benzinga.com
Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings
U.S. stocks rose Tuesday: Dow +0.24%, Nasdaq +0.39%, S&P 500 +0.18%. Communication services led; energy fell. AutoZone beat earnings; oil dropped 2.4%.
1 month ago globenewswire.com
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics…
-
2 months ago benzinga.com
Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6
Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.
-
2 months ago benzinga.com
Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 7.14 percent increase over losses…
2 months ago globenewswire.com
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior…
-
3 months ago benzinga.com
Compass Therapeutics Abstract Accepted For Oral Presentation At Upcoming European Society For Medical Oncology Congress
Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today…
3 months ago globenewswire.com
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
3 months ago seekingalpha.com
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. CMPX's lead asset, tovecimig, showed strong PFS benefit in BTC, but OS crossover contamination…
4 months ago seekingalpha.com
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
4 months ago marketbeat.com
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific…
5 months ago globenewswire.com
Compass Therapeutics to Participate in Upcoming June Investor Events
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
-
5 months ago benzinga.com
Compass Therapeutics' CTX-8371 Dual PD-1/PD-L1 Bispecific Shows Durable Monotherapy Responses In Advanced Checkpoint-Resistant Cancers With Favorable Safety Profile
CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with…
5 months ago globenewswire.com
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
5 months ago gurufocus.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PR Newswire
5 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are…
5 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such investors are…
5 months ago gurufocus.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PR Newswire
5 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are…
5 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such investors are…
5 months ago globenewswire.com
Compass Therapeutics to Participate in Upcoming May Investor Events
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
5 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are…
-
6 months ago benzinga.com
Compass Therapeutics Q1 EPS $(0.10), Inline
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.12) per share from the…
-
6 months ago benzinga.com
Canaccord Genuity Maintains Buy on Compass Therapeutics, Lowers Price Target to $7
Canaccord Genuity analyst John Newman maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $13 to $7.
-
6 months ago benzinga.com
Citizens Reiterates Market Outperform on Compass Therapeutics, Maintains $10 Price Target
Citizens analyst Reni J. Benjamin reiterates Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and maintains $10 price target.
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $24 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $24 price target.
6 months ago benzinga.com
Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings
U.S. stocks trade lower on Monday, with Dow falling 0.1%. Verizon beats Q1 earnings, raises FY26 guidance. European shares mixed, Asian markets close mixed.
6 months ago benzinga.com
Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
Compass Therapeutics says tovecimig misses overall survival endpoint in biliary tract cancer study, but data shows progression-free survival and response rates.
6 months ago benzinga.com
US Stocks Mixed; Nasdaq Falls Over 100 Points
US stocks mixed on Monday, Nasdaq falls 0.56% while Dow gains 0.06%. Energy shares up 1%. Domino's reports worse-than-expected results.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
6 months ago benzinga.com
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations, shares fall 3.8%. Other stocks also decline.
-
6 months ago benzinga.com
Market-Moving News for April 27th
QCOM: 13% | OpenAI Eyes 'AI Agent' Smartphone With Qualcomm And MediaTek, Targets App-Free Experience By 2028: Report CMPX: -14% | Compass Therapeutics To Host Webcast On April 27 To Review Topline
6 months ago benzinga.com
Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the company for $11.75 billion, $2 higher than current price.
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
6 months ago benzinga.com
9 Health Care Stocks With Whale Alerts In Today's Session
9 Health Care Stocks With Whale Alerts In Today's Session